Evidence map›Paper›PMID 28363154›Full record

ArticleEuropean journal of medicinal chemistry2017

Synthesis, stability and mechanistic studies of potent anticryptococcal hexapeptides.

Kitika Shenmar, Krishna K Sharma, Nishima Wangoo, Indresh K Maurya, Vinod Kumar, Shabana I Khan, Melissa R Jacob, Kulbhushan Tikoo, Rahul Jain

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Meta-Position of PheMolecules (Basel, Switzerland) · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kitika ShenmarDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab, 160 062, India.
Krishna K SharmaDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab, 160 062, India.
Nishima WangooDepartment of Applied Sciences, University Institute of Engineering and Technology (U.I.E.T.), Panjab University, Sector-25, Chandigarh, 160014, India.
Indresh K MauryaDepartment of Microbial Biotechnology, Panjab University, Sector-14, Chandigarh, 160014, India.
Vinod KumarDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab, 160 062, India.
Shabana I KhanNational Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS 38677, USA.
Melissa R JacobNational Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS 38677, USA.
Kulbhushan TikooDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab, 160 062, India.
Rahul JainDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab, 160 062, India. Electronic address: rahuljain@niper.ac.in.

Funding

NEW DRUGS FOR OPPORTUNISTIC INFECTIOUS DISEASESR01AI027094 · NIAID · UNIVERSITY OF MISSISSIPPI · PI CLARK, ALICE M. · 1989 to 2013
$4.4M
NIAID NIH HHS R01 AI027094
6 · The paper itself

Abstract

The growing incidents of cryptococcosis in immuno-compromised patients have created a need for novel drug therapies capable of eradicating the disease. The peptide-based drug therapy offers many advantages over the traditional therapeutic agents, which has been exploited in the present study by synthesizing a series of hexapeptides that exhibits promising activity against a panel of Gram-negative and Gram-positive bacteria and various pathogenic fungal strains; the most exemplary activity was observed against Cryptococcus neoformans. The peptides 3, 24, 32 and 36 displayed potent anticryptococcal activity (IC

Indexed as

Anti-Bacterial AgentsAntifungal AgentsCell MembraneCryptococcus neoformansDrug StabilityInhibitory Concentration 50Methicillin-Resistant Staphylococcus aureusPeptidesStaphylococcus aureusAnti-Bacterial AgentsAntifungal AgentsPeptidesAmphiphilic hexapeptidesAnticryptococcalElectron microscopyProteolysisSolid phase peptide synthesis

Identifiers

PMID28363154
PMCPMC5476684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.